At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 91 enrolled
Drug / intervention
CCH-aaes +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
APHRODITE-1: A Phase 2, Open Label, Self-Controlled Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks in Adult Females
In Brief
A Phase 2 clinical trial evaluating CCH-aaes and Antifibrinolytic Agent for Edematous Fibrosclerotic Panniculopathy and Cellulite. Completed, enrolled 91 participants across 13 sites.
Detailed Summary
The study will evaluate the effect of different doses, strengths (concentrations), diluent additives, depths of injection, and methods of injection on the severity of bruising potentially induced by QWO (collagenase clostridium histolyticum-aaes \[CCH-aaes\]).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEdematous Fibrosclerotic Panniculopathy, Cellulite
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedJun 2022
Enrollment StartJun 2022
Primary CompletionJan 2023
Study CompletionJun 2023
TodayJul 2026
First PostedJun 15, 2022
Enrollment StartJun 15, 2022
Primary CompletionJan 3, 2023
Study CompletionJun 21, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.0 years ago
Interventions
CCH-aaesdrug
Administered by subcutaneous injection.
Antifibrinolytic Agentdrug
Self-administered by participants enrolled in Cohort 7.